OmniaBio Resource Centre

iPSCs are created by reprogramming differentiated somatic cells, which allows them to exhibit properties similar to embryonic stem cells. From a scale-up and manufacturing perspective, groups need the right support to achieve their goals in a time-efficient and cost-effective manner.

This blog will explore how developing customized solutions for system closure and process automation solves key technical bottlenecks, advances the manufacturing of, and ultimately patient access to, these life-saving medicines.